Pfizer and its German partner BioNTech said on Friday they have requested the U.S. Food and Drug Administration to expand the emergency use of their COVID-19 vaccine in adolescents aged 12 to 15.
In March, the drugmakers said the vaccine was found to be safe, effective and produced robust antibody responses in 12- to 15-year olds in a clinical trial.
Whether COVID-19 vaccines work and are safe to use on children is one of the big questions drugmakers are trying to answer. Inoculating children and young people is considered a critical step toward reaching “herd immunity” and taming the pandemic, according to experts.
- Health Canada approves drug to treat hot flashes for some cancer patients
- Manitoba’s largest hospital still recovering after cyberattack
- Toronto Public Health investigating legionnaires’ disease outbreak near downtown core
- Hamilton ‘black soot’ not expected to pose long-term risk, public health says
Get weekly health news
The companies plan to request similar rulings by other regulatory authorities globally in the coming days.
The Pfizer/BioNTech two-shot vaccine is already authorized for use in people as young as 16.
Comments
Want to discuss? Please read our Commenting Policy first.